journal article·2025-09-10

Local Delivery of Molecular Hydrogen by Fluorinated Zeolitic Imidazole Framework Nanosheets Boosts Cancer Immunotherapy

Xiang Liu, Weidong Wang, Tianze Wu, Jianing Li, Yimin Gong, Dan Luo, Xianling Guo, Mingli Deng, Yannan Yang

ACS Applied Materials & Interfaces· Volume 17· Issue 36
Publisher page

Abstract

Identifying strategies to improve the efficacy of the immune checkpoint blockade (ICB) remains a major clinical need. Based on the high tissue penetration capability of hydrogen molecules (H 2 ) and their immunomodulatory effects, this work proposes a local gas delivery strategy targeting the tumor microenvironment for high-efficacy hydrogen immunotherapy. We synthesized hepta-fluorinated zeolitic imidazolate frameworks nanosheet (F 7 -ZIF) with high H 2 payload, sustained acid-responsive gas release property, and biodegradation. H 2 -loaded F 7 -ZIF (F 7 -ZIF/H 2 ) effectively released H 2 and Zn 2+ to induce significant mitochondrial damage and cell apoptosis. More importantly, F 7 -ZIF/H 2 considerably upregulated the expression of CD47 (“do not eat me” signal) on tumor cells, which increases target accessibility for anti-CD47 antibody, thereby enhancing their binding efficiency. RNA-seq suggests that the CD47 antibody not only blocks the “do not eat me” signal (mediated by CD47-SIRPα interactions) but also engages Fc receptors on macrophages through its Fc region to trigger antibody-dependent cellular phagocytosis. In melanoma tumor models with small (∼50 mm 3 ) and large sized established tumors (∼200 mm 3 ), the combination of F 7 -ZIF/H 2 and anti-CD47 reaches 90% and 83% of tumor inhibition rate, respectively, compared to free anti-CD47. When further combined with anti-PD-L1, the therapeutic system triggers systemic T cell immunity that rejects the progression of both primary and distal tumors. This work provides insights into gas-assisted cancer immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hydrogen's biological and therapeutic effects · Nanoplatforms for cancer theranostics · Anesthesia and Neurotoxicity Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials

Fudan University

Obstetrics and Gynecology Hospital, State Key Laboratory of Genetic Engineering, Institute of Reproduction and Development, Children’s Hospital

Department of Oncology, Shanghai Tenth People’s Hospital

Tongji University

Tongji University Cancer Center

Institute of Optoelectronics, Fudan University

South Australian immunoGENomics Cancer Institute

The University of Adelaide

Funding

National Health and Medical Research Council · National Natural Science Foundation of China

References (39)

Show source-provided references
1. 10.1126/science.ade852010.1126/science.ade8520 ↗
2. 10.1158/2159-8290.CD-20-181510.1158/2159-8290.CD-20-1815 ↗
3. 10.1038/s41586-025-08626-710.1038/s41586-025-08626-7 ↗
4. 10.1016/j.celbio.2025.10002510.1016/j.celbio.2025.100025 ↗
5. 10.1038/s43018-025-00919-010.1038/s43018-025-00919-0 ↗
6. 10.1158/1538-7445.AM2025-347110.1158/1538-7445.AM2025-3471 ↗
7. 10.1038/s41467-022-35096-610.1038/s41467-022-35096-6 ↗
8. 10.1002/advs.20230521710.1002/advs.202305217 ↗
9. 10.1038/s41467-023-41470-910.1038/s41467-023-41470-9 ↗
10. 10.1002/adhm.20190046310.1002/adhm.201900463 ↗
11. 10.1021/jacs.4c1045710.1021/jacs.4c10457 ↗
12. 10.1002/adfm.20231453610.1002/adfm.202314536 ↗
13. 10.1038/s41467-024-52006-010.1038/s41467-024-52006-0 ↗
14. 10.1126/science.116630410.1126/science.1166304 ↗
15. 10.1016/j.cej.2021.12991710.1016/j.cej.2021.129917 ↗
16. 10.1002/advs.20210196510.1002/advs.202101965 ↗
17. 10.1038/s41467-021-21618-110.1038/s41467-021-21618-1 ↗
18. 10.1038/s41467-018-06630-210.1038/s41467-018-06630-2 ↗
19. 10.1002/adma.20230877410.1002/adma.202308774 ↗
20. 10.1016/j.chempr.2022.07.00110.1016/j.chempr.2022.07.001 ↗
21. 10.1002/adma.20241492910.1002/adma.202414929 ↗
22. 10.1038/s41467-022-29938-610.1038/s41467-022-29938-6 ↗
23. 10.1002/adma.20240464510.1002/adma.202404645 ↗
24. 10.1039/D2CS00442A10.1039/D2CS00442A ↗
25. 10.1002/adma.20220795510.1002/adma.202207955 ↗
26. 10.1021/acsnano.3c0996810.1021/acsnano.3c09968 ↗
27. 10.1021/acsnano.4c0808510.1021/acsnano.4c08085 ↗
28. 10.1021/ja510823h10.1021/ja510823h ↗
29. 10.1002/adma.20220958910.1002/adma.202209589 ↗
30. 10.1002/adhm.20230190110.1002/adhm.202301901 ↗
31. 10.1038/s41467-020-18745-610.1038/s41467-020-18745-6 ↗
32. 10.1038/nature2134910.1038/nature21349 ↗
33. 10.1016/j.ijpharm.2019.11863610.1016/j.ijpharm.2019.118636 ↗
34. 10.1002/adma.20241805310.1002/adma.202418053 ↗
35. 10.3389/fphar.2021.66272610.3389/fphar.2021.662726 ↗
36. 10.1126/sciimmunol.add115310.1126/sciimmunol.add1153 ↗
37. 10.1126/sciadv.abl917110.1126/sciadv.abl9171 ↗
38. 10.1136/jitc-2021-00346410.1136/jitc-2021-003464 ↗
39. 10.1039/D2BM01354A10.1039/D2BM01354A ↗